The 12 references in paper M. Mustafina Kh., O. Tsvetkova A., М. Мустафина Х., О. Цветкова А. (2014) “Фармакогенетический эффект полиморфизма гена ADRB2 на терапию хронической обструктивной болезни легких // Pharmacogenetic effect of ADRB2 gene polymorphism on therapeutic response in chronic obstructive pulmonary disease” / spz:neicon:pulmonology:y:2013:i:3:p:21-24

1
Global initiative for chronic obstructive lung disease (GOLD). [Электронный ресурс]. Global strategy for the diagnosis, management of chronic obstructive pulmonary disease (Updated 2010). http: www.goldcopd.com (Date last updated: November 2010).
(check this in PDF content)
2
Murray C.J., Lopez A.D. Global mortality, disability, and the contribution of risk factors: Global burden of disease study. Lancet 1997; 349 (9063): 1436–1442.
(check this in PDF content)
3
Чучалин А.Г.(ред.). Хроническая обструктивная болезнь легких: практическое руководство для врачей. М.: 2004.
(check this in PDF content)
4
Визель А.А., Визель И.Ю.Хроническая обструктивная болезнь легких: воспаление как ключевая проблема. Практ. Мед. 2009; 3 (35): 22?24.
(check this in PDF content)
5
Ноников В.Е.Хроническая обструктивная болезнь легких: современные подходы к терапии. Consilium Medicum 2001; 3 (12): 584–587.
(check this in PDF content)
6
Hall I.P.β2-adrenoceptor polymorphisms: are they clinically important? Thorax 1996; 51: 351–353.
(check this in PDF content)
7
Сычев Д.А., Муслимова О.В., Гаврисюк Е.В. и др. Фармакогенетические технологии персонализированной медицины: оптимизация применения лекарственных средств. Terra Medica 2011; 1: 4–9.
(check this in PDF content)
8
Thomsen M., Nordestgaard B.G.β2-Adrenergic receptor polymorphisms, asthma and COPD: two large populationbased studies. Eur. Respir. J. 2012; 39: 558–566.
(check this in PDF content)
9
Гланц С. Медико-биологическая статистика. Пер. с англ. М.: Практика; 1998.
(check this in PDF content)
10
Hizawa N., Makita H., Nashra Y. et al. Beta2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD. Chest 2007; 132 (5): 1485–1486.
(check this in PDF content)
11
Bleecker E.R., Meyers D.A.ADRB2 Polymorphism and budesonide / formoterol response in chronic obstructive pulmonary disease. Chest 2012; 142 (2):320–328.
(check this in PDF content)
12
Kim W.J., Oh Y.M., Sung J. et al. Lung function response to 12-week treatment with combined inhalation of long-acting β2-agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease. Lung 2008; 186 (6): 381–386.
(check this in PDF content)